Literature DB >> 28533894

A Scaffold Merging Approach to Hsp90 C-terminal Inhibition: Synthesis and Evaluation of a Chimeric Library.

Rachel E Davis1, Zheng Zhang1, Brian S J Blagg1.   

Abstract

Inhibition of the Hsp90 C-terminus is an attractive therapeutic paradigm for the treatment of cancer, however the developmental space of C-terminal inhibitors is limited. It was hypothesized that the combination of two previously identified scaffolds into a single structure could provide a platform for which to probe the three-dimensional space within the Hsp90 C-terminal binding pocket. The resulting chimeric compounds displayed anti-proliferative activity at low micromolar concentrations and manifested inhibitory activity in an Hsp90-dependent rematuration assay. Initial structure-activity relationships suggest that this new scaffold binds Hsp90 in a conformation different from that of the parent compounds, and consequently, provides a new opportunity to develop more efficacious inhibitors of the Hsp90 C-terminal binding pocket.

Entities:  

Year:  2017        PMID: 28533894      PMCID: PMC5437984          DOI: 10.1039/C6MD00377J

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  27 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

Review 2.  Targeting heat shock proteins in cancer.

Authors:  Gaëtan Jego; Adonis Hazoumé; Renaud Seigneuric; Carmen Garrido
Journal:  Cancer Lett       Date:  2010-11-13       Impact factor: 8.679

3.  Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.

Authors:  Takrima Sadikot; Megan Swink; Jeffery D Eskew; Douglas Brown; Huiping Zhao; Bhaskar R Kusuma; Roger A Rajewski; Brian S J Blagg; Robert L Matts; Jeffrey M Holzbeierlein; George A Vielhauer
Journal:  Assay Drug Dev Technol       Date:  2013-10-15       Impact factor: 1.738

4.  Identification and initial SAR of silybin: an Hsp90 inhibitor.

Authors:  Huiping Zhao; Gary E Brandt; Lakshmi Galam; Robert L Matts; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2010-12-28       Impact factor: 2.823

5.  Switchable enantioseparation based on macromolecular memory of a helical polyacetylene in the solid state.

Authors:  Kouhei Shimomura; Tomoyuki Ikai; Shigeyoshi Kanoh; Eiji Yashima; Katsuhiro Maeda
Journal:  Nat Chem       Date:  2014-04-13       Impact factor: 24.427

Review 6.  Targeting the dynamic HSP90 complex in cancer.

Authors:  Jane Trepel; Mehdi Mollapour; Giuseppe Giaccone; Len Neckers
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

7.  Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.

Authors:  Huiping Zhao; Gaurav Garg; Jinbo Zhao; Elisabetta Moroni; Antwan Girgis; Lucas S Franco; Swapnil Singh; Giorgio Colombo; Brian S J Blagg
Journal:  Eur J Med Chem       Date:  2014-10-14       Impact factor: 6.514

8.  Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line.

Authors:  Yuanming Lu; Sabah Ansar; Mary L Michaelis; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2008-12-25       Impact factor: 3.641

9.  (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor.

Authors:  Zhengyu Yin; Ellen C Henry; Thomas A Gasiewicz
Journal:  Biochemistry       Date:  2009-01-20       Impact factor: 3.162

10.  Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90.

Authors:  Joseph A Burlison; Len Neckers; Andrew B Smith; Anthony Maxwell; Brian S J Blagg
Journal:  J Am Chem Soc       Date:  2006-12-06       Impact factor: 15.419

View more
  3 in total

1.  Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors.

Authors:  Katherine M Byrd; Caitlin N Kent; Brian S J Blagg
Journal:  ChemMedChem       Date:  2017-11-30       Impact factor: 3.466

2.  Novel C-terminal heat shock protein 90 inhibitors target breast cancer stem cells and block migration, self-renewal, and epithelial-mesenchymal transition.

Authors:  Chitra Subramanian; Patrick T Grogan; Ton Wang; Joseph Bazzill; Ang Zuo; Peter T White; Avinaash Kalidindi; Dawn Kuszynski; Grace Wang; Brian S J Blagg; Mark S Cohen
Journal:  Mol Oncol       Date:  2020-05-15       Impact factor: 6.603

3.  Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations.

Authors:  Tihomir Tomašič; Martina Durcik; Bradley M Keegan; Darja Gramec Skledar; Živa Zajec; Brian S J Blagg; Sharon D Bryant
Journal:  Int J Mol Sci       Date:  2020-09-20       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.